Products for Research Use Only

JAK/HDAC-IN-2

CAT: 0804-HY-149283Size: 1 EachDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-149283Size:1 Each
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
JAK/HDAC-IN-2 is a potent 2-amino-4-phenylaminopyrimidine JAK/HDAC dual-target inhibitor. JAK/HDAC-IN-2 potently inhibits HDAC3/6 and JAK1/2 at nanomolar levels. JAK/HDAC-IN-2 has proapoptotic activity and inhibits histone deacetylation and STAT3 phosphorylation. JAK/HDAC-IN-2 presents remarkable antiproliferative activity in both hematological malignancies and solid cancers[1].
CAS Number
3029138-43-7
UNSPSC
12352005
Target
Apoptosis; HDAC; JAK
Type
Reference compound
Related Pathways
Apoptosis; Cell Cycle/DNA Damage; Epigenetics; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/jak-hdac-in-2.html
Solubility
10 mM in DMSO
Smiles
CC(NS(C1=CC(NC2=NC(NC3=CC=C(C=C3)OCCCCCCC(NO)=O)=NC=C2C)=CC=C1)(=O)=O)(C)C
Molecular Formula
C28H38N6O5S
Molecular Weight
570.70
References & Citations
[1]Qianqian Qiu, et al. Exploration of Janus Kinase (JAK) and Histone Deacetylase (HDAC) Bispecific Inhibitors Based on the Moiety of Fedratinib for Treatment of Both Hematologic Malignancies and Solid Cancers. J Med Chem. 2023 Apr 27;66 (8) :5753-5773.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
HDAC; HDAC1; HDAC10; HDAC11; HDAC2; HDAC3; HDAC4; HDAC5; HDAC6; HDAC7; HDAC8; HDAC9; JAK1; JAK2; JAK3; Tyk2